David Huang, in Broadview Hts, OH - General Practice

David Huang, is a General Practice physician based in Broadview Hts, Ohio. David Huang is licensed to practice in Ohio (license number 30.025569) and his current practice location is 2828 Lydia Dr, Broadview Hts, Ohio. He can be reached at his office (for appointments etc.) via phone at (216) 854-3725.

NPI number for David Huang is 1104302520 and his current mailing address is 2828 Lydia Dr, Broadview Hts, Ohio. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1104302520.

Contact Information

	David Huang,
	2828 Lydia Dr, Broadview Hts, OH 44147
	(216) 854-3725
	Not Available

Physician's Profile

Full Name	David Huang
Gender	Male
Speciality	General Practice
Location	2828 Lydia Dr, Broadview Hts, Ohio
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1104302520
Provider Enumeration Date: 07/18/2018
Last Update Date: 08/21/2018

Medical Identifiers

Medical identifiers for David Huang such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1104302520	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	30.025569 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. David Huang is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
David Huang, 2828 Lydia Dr, Broadview Hts, OH 44147-1720 Ph: () -	David Huang, 2828 Lydia Dr, Broadview Hts, OH 44147 Ph: (216) 854-3725

News Archive

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

A new paper discusses an intriguing new mechanism of immune evasion traceable to specific mutations in the B.1.427/B.1.429 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Two Protein Science authors selected as winners of 2015 Best Paper Awards

The Protein Society, an international, trans-disciplinary community of scientists dedicated to protein research, announces the third annual selection of two Protein Science authors as winners of the 2015 Best Paper Awards.

Scientists back the use of maize as an efficient 'factory' for protein-based pharmaceutical products

Scientists from the Universidad de Lleida (University of Lleida) have published a study confirming that maize seeds are an effective and sure platform within molecular agriculture to alleviate diseases. Over the next few years AIDS could be one of the first diseases to benefit from these results, although regulations for this technology are being developed at the same time as research is being undertaken.

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

David Huang, - General Practice in Broadview Hts, OH